瑞巴派特联合胃复春治疗慢性萎缩性胃炎患者的疗效分析  

Analysis of the curative effect of rebamipide combined with Weifuchun in the treatment of patients with chronic atrophic gastritis

作　　者：张燚 徐杰 余华良 ZHANG Yi;XU Jie;YU Hua-liang(Department of Gastroenterology,Suzhou BOE Hospital,Suzhou 215200,China)

机构地区：[1]苏州京东方医院消化内科,215200

出　　处：《中国实用医药》2025年第7期75-78,共4页China Practical Medicine

摘　　要：目的探究瑞巴派特联合胃复春治疗慢性萎缩性胃炎患者的疗效。方法选取80例慢性萎缩性胃炎患者作为研究对象,将其按照随机数字表法分为研究组与对照组,每组40例。研究组单一应用胃复春治疗,研究组联合应用胃复春与瑞巴派特进行治疗。对比两组治疗效果、不良反应发生率、临床症状评分、血清学指标[白细胞介素-1β(IL-1β)、可溶性白细胞介素2受体(sIL-2R)、胃泌素(GAS)、胃动素(MTL)]水平。结果研究组总有效率97.5%较对照组的77.5%高(P<0.05)。研究组不良反应发生率2.5%较对照组的25.0%低(P<0.05)。治疗后,研究组胃脘疼痛、胃中嘈杂、口苦口干、嗳气泛酸评分分别为(1.02±0.08)、(0.31±0.06)、(0.37±0.04)、(0.56±0.13)分,均较对照组的(1.78±0.22)、(0.92±0.09)、(1.62±0.09)、(1.51±0.11)分低(P<0.05)。治疗后,研究组IL-1β(31.68±7.81)ng/L、sIL-2R(313.48±23.79)U/ml、GAS(109.18±11.83)pg/ml、MTL(124.88±13.74)pg/ml均较对照组的(64.62±8.35)ng/L、(354.79±24.37)U/ml、(152.79±12.39)pg/ml、(169.62±14.71)pg/ml低(P<0.05)。结论瑞巴派特联合胃复春治疗慢性萎缩性胃炎疗效显著,安全性高,且有助于改善患者临床症状与血清学水平,临床价值显著,值得推广。Objective To explore the curative effect of rebamipide combined with Weifuchun in the treatment of patients with chronic atrophic gastritis.Methods 80 patients with chronic atrophic gastritis were selected as research subjects and divided into study group and control group according to random numerical table,with 40 cases in each group.The study group was treated with Weifuchun alone,and the study group was treated with Weifuchun combined with rebamipide.Comparison of therapeutic effect,incidence of adverse reactions,clinical symptom score and serological indexes[interleukin-1β(IL-1β),soluble interleukin-2 receptor(sIL-2R),gastrin(GAS)and motilin(MTL)]between the two groups.Results The total effective rate of 97.5%in the study group was higher than 77.5%in the control group(P<0.05).The incidence of adverse reactions of 2.5%in the study group was lower than 25.0%in the control group(P<0.05).After treatment,the scores of epigastric pain,gastric noise,bitter mouth and dry mouth,and belching and acidity were(1.02±0.08),(0.31±0.06),(0.37±0.04),and(0.56±0.13)points,which were lower than(1.78±0.22),(0.92±0.09),(1.62±0.09),and(1.51±0.11)points in the control group(P<0.05).After treatment,the study group had IL-1βof(31.68±7.81)ng/L,sIL-2R of(313.48±23.79)U/ml,GAS of(109.18±11.83)pg/ml,and MTL of(124.88±13.74)pg/ml,which were lower than(64.62±8.35)ng/L,(354.79±24.37)U/ml,(152.79±12.39)pg/ml,and(169.62±14.71)pg/ml in the control group(P<0.05).Conclusion The combination of rebamipide and Weifuchun has significant therapeutic effects and high safety in the treatment of chronic atrophic gastritis,and can help improve patients'clinical symptoms and serological levels.It has significant clinical value and is worthy of promotion.

关 键 词：慢性萎缩性胃炎 瑞巴派特 胃复春 胃脘痛 

分 类 号：R259[医药卫生—中西医结合]